Ovarian cancer is the most lethal gynecological malignancy in developed countries. This is
due to the lack of specific symptoms that hinder early diagnosis and to the high relapse rate after
treatment with radical surgery and chemotherapy. Hence, novel therapeutic modalities to improve
clinical outcomes in ovarian malignancy are needed. Progress in gene therapy has allowed the
development of several strategies against ovarian cancer. Most are focused on the design of improved
vectors to enhance gene delivery on the one hand, and, on the other hand, on the development
of new therapeutic tools based on the restoration or destruction of a deregulated gene, the use of
suicide genes, genetic immunopotentiation, the inhibition of tumour angiogenesis, the alteration
of pharmacological resistance, and oncolytic virotherapy. In the present manuscript, we review
the recent advances made in gene therapy for ovarian cancer, highlighting the latest clinical trials
experience, the current challenges and future perspectives.This research was supported by the Fundación Mutua Madrileña by the proyect FMM-AP16683-2017,
Consejería de Salud Junta de Andalucía (PI-0089-2017) and from the Chair “Doctors Galera-Requena in cancer
stem cell research”